Julie Pollock

Julie Pollock

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2014 in eLife
Verified
Journal Article
Open access
JNJerome C Nwachukwu
Jerome C Nwachukwu
SSSathish Srinivasan
Sathish Srinivasan
NBNelson E Bruno
Nelson E Bruno
APAlexander A Parent
Alexander A Parent
THTravis S Hughes
Travis S Hughes
KNKendall W Nettles
Kendall W Nettles
Resveratrol has beneficial effects on aging, inflammation and metabolism, which are thought to result from activation of the lysine deacetylase, sirtuin 1 (SIRT1), the cAMP pathway, or AMP-activated protein kinase. In this study, we report that resveratrol acts as a pathway-selective estrogen receptor-α (ERα) ligand to modulate the inflammatory response but not cell proliferation. A crystal structure of the ERα ligand-binding domain (LBD) as a complex with resveratrol revealed a unique perturbation of the coactivator-binding surface, consistent with an altered coregulator recruitment profile. Gene expression analyses revealed significant overlap of TNFα genes modulated by resveratrol and estradiol. Furthermore, the ability of resveratrol to suppress interleukin-6 transcription was shown to require ERα and several ERα coregulators, suggesting that ERα functions as a primary conduit for resveratrol activity.

25 April 2012 in ACS Chemical Biology
Verified
Journal Article
Closed access
JPJulie Pollock
Julie Pollock
MLMichelle D. Larrea
Michelle D. Larrea
JJJeff S. Jasper
Jeff S. Jasper
DMDonald P. McDonnell
Donald P. McDonnell
DMDewey G. McCafferty
Dewey G. McCafferty

13 February 2017 in Discover Oncology
Verified
Journal Article
Open access
PDF file
JCJessica L. Christenson
Jessica L. Christenson
KBKiel T. Butterfield
Kiel T. Butterfield
NSNicole S. Spoelstra
Nicole S. Spoelstra
JNJohn D. Norris
John D. Norris
JJJatinder S. Josan
Jatinder S. Josan
JRJennifer K. Richer
Jennifer K. Richer
Triple-negative breast cancer (TNBC) has a faster rate of metastasis compared to other breast cancer subtypes, and no effective targeted therapies are currently FDA-approved. Recent data indicate that the androgen receptor (AR) promotes tumor survival and may serve as a potential therapeutic target in TNBC. Studies of AR in disease progression and the systemic effects of anti-androgens have been hindered by the lack of an AR-positive (AR+) immunocompetent preclinical model. In this study, we identified the transgenic MMTV-PyMT (mouse mammary tumor virus-polyoma middle tumor-antigen) mouse mammary gland carcinoma model of breast cancer and Met-1 cells derived from this model as tools to study the role of AR in breast cancer progression. AR protein expression was examined in late-stage primary tumors and lung metastases from MMTV-PyMT mice as well as in Met-1 cells by immunohistochemistry (IHC). Sensitivity of Met-1 cells to the AR agonist dihydrotestosterone (DHT) and anti-androgen therapy was examined using cell viability, migration/invasion, and anchorage-independent growth assays. Late-stage primary tumors and lung metastases from MMTV-PyMT mice and Met-1 cells expressed abundant nuclear AR protein, while negative for estrogen and progesterone receptors. Met-1 sensitivity to DHT and AR antagonists demonstrated a reliance on AR for survival, and AR antagonists inhibited invasion and anchorage-independent growth. These data suggest that the MMTV-PyMT model and Met-1 cells may serve as valuable tools for mechanistic studies of the role of AR in disease progression and how anti-androgens affect the tumor microenvironment.

1 May 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DGDavid M. Gooden
David M. Gooden
DSDawn M.Z. Schmidt
Dawn M.Z. Schmidt
JPJulie Pollock
Julie Pollock
AKAmi M. Kabadi
Ami M. Kabadi
DMDewey G. McCafferty
Dewey G. McCafferty

1 April 2018 in Journal of Electroanalytical Chemistry
Verified
Journal Article
Closed access
MPMichael J. Pannell
Michael J. Pannell
EDElizabeth E. Doll
Elizabeth E. Doll
NLNajwa Labban
Najwa Labban
MWMulugeta B. Wayu
Mulugeta B. Wayu
JPJulie Pollock
Julie Pollock
MLMichael C. Leopold
Michael C. Leopold

14 August 2018 in Science Signaling
Verified
Journal Article
Open access
PDF file
SISirish K. Ippagunta
Sirish K. Ippagunta
JPJulie Pollock
Julie Pollock
NSNaina Sharma
Naina Sharma
WLWenwei Lin
Wenwei Lin
TCTaosheng Chen
Taosheng Chen
HHHans R. Haecker
Hans R. Haecker
A phenotypic screening platform identifies specific inhibitors of individual TLR pathways.